Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.26 and traded as high as $0.2636. Northwest Biotherapeutics shares last traded at $0.2592, with a volume of 1,867,648 shares trading hands.
Northwest Biotherapeutics Price Performance
The stock has a market capitalization of $412.19 million, a P/E ratio of -0.01 and a beta of -0.86. The company’s 50 day simple moving average is $0.26 and its two-hundred day simple moving average is $0.25.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last announced its earnings results on Friday, November 14th. The biotechnology company reported ($18.22) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Recommended Stories
- Five stocks we like better than Northwest Biotherapeutics
- The buying spree that no one is talking about
- How to collect $500-$800 weekly (BlackRock’s system)
- Trump’s AI Secret: 100X Faster Than Nvidia
- NEW LAW: Congress Approves Setup For Digital Dollar?
- They just tried to kill gold
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
